Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2005

View Archived Issues

Hydroxytyrosol protects the kidney against ciclosporin-evoked oxidative stress

ICA-17043 induces sustained improvements in patients with sickle cell anemia

Cabergoline reported more effective than L-dopa in idiopathic RLS

Quetiapine shows promise in the treatment of bipolar depression

ACT 4 safety study begins for RSD-1235

CH-1504 completes phase Ia trial, begins phase Ib

BioWa inlicenses anti-FGF8 antibody

NIH grant for Friedreich's ataxia research

Maxygen supported in preventative HIV vaccine efforts

GSK Biologicals and Aeras team up on TB vaccine development

Nektar Therapeutics completes acquisition of Aerogen

CepTor to receive milestone payment for Myodur IND filing

FDA clears phase I study of neural stem cells to treat Batten disease

IRB approval for phase I study of PRX-302 for recurrent prostate cancer

Recombinant protein with exemplary thrombolytic and antithrombotic properties

Cloretazine receives fast track designation for elderly poor-risk AML patients

Brx-019 boosts immune response in diabetic mice

Armodafinil improves wakefulness and cognition in patients with sleep disorders

Interim data shows a good safety profile for Cand5 in wet AMD patients

Sirna-027 improves visual acuity of patients with CNV secondary to AMD

Update on the long-term effects and safety of anecortave acetate in AMD

Tesmilifene-mitoxantrone combination active in refractory prostate cancer

Recent patents describe novel therapeutic agents for depression, anxiety, etc.

Novel agents for HIV infection imparted in recent patent literature

Novel anticoagulant agents thrombotic disorders revealed

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...